Navigation Links
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Date:4/26/2008

DE (n=1) and 12 percent of

patients receiving adefovir (n=5) experienced a serious adverse event.

-- No deaths were observed in either treatment group.

-- No patients in the BARACLUDE arm and one patient in the adefovir arm

experienced an ALT flare (defined as ALT greater than two times

baseline and greater than 10 times the upper limit of normal).

About the Study

The E.A.R.L.Y. study (ETV-079) is a randomized, open-label, comparative viral kinetics study of antiviral-naive chronic HBeAg-positive patients evaluating antiviral activity as measured by mean reduction in viral load, or levels of hepatitis B virus (HBV DNA) in the blood. HBeAg or e-antigen, is a viral protein associated with hepatitis B infections, and is found in the blood only when there is virus present.

The primary endpoint for the study was mean reduction in HBV DNA levels at week 12. The secondary endpoints included the mean change in viral load from baseline through week 96, the proportion of patients in each treatment group who achieved ALT normalization, HBeAg loss and HBe seroconversion, and safety.

Sixty-nine patients were randomized in the study and of these, 65 completed the first 12 weeks. Patients in this study received either 0.5 mg of BARACLUDE(R) (entecavir) once daily (n=33) or 10 mg of adefovir once daily (n=32) for a minimum of 52 weeks. Patients in the BARACLUDE treatment group had a mean baseline viral load of 10.26 log(10) copies/mL. Patients in the adefovir treatment group had a mean baseline viral load of 9.88 log(10) copies/mL.

According to study protocol, patients who achieved a treatment response at 52 weeks discontinued treatment and entered a follow-up monitoring phase. Three BARACLUDE-treated patients and four adefovir-treated patients met this criterion and entered the follow-up monitoring phase lasting up to 48 weeks. Patients who did not achieve a treatment response at 52 weeks continued on study
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Many Heart Attack Patients Dont Get Best Emergency Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  AnaptysBio, Inc., a ... antibodies, today announced the appointment of Marco ... Londei will lead the preclinical and clinical development ... "We are pleased to welcome Dr. Londei to ... , President and Chief Executive Officer of AnaptysBio. ...
(Date:10/20/2014)... -- Norgine B.V. today announced that the ... preparation, NER1006, presented at the 79 th Annual ... Philadelphia, PA , has met its ... endpoint of cleansing success. The study demonstrated high quality ... in screening colonoscopy patients. [1] (Logo: ...
(Date:10/19/2014)... , Deutschland, October 19, 2014 ... gefragt. Das Problem dabei ist, dass ... mit der Kompetenz zu teilen. Es ... deshalb freuen wir uns umso mehr, dass es ... ihre Gepflogenheiten bei Kühlketten aufzuschreiben - mit einem ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2
(Date:10/20/2014)... 2014 Do you ever feel difficulty ... a wonderful app Metassessor for teachers, specialists and parents. ... helped its client “Intervention Development LLC” to launch Metassessor ... designed for iOS 4.3 or later and is Compatible ... optimized for iPhone 5. It is now available on ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Recently, BambooIndustry.com, ... has unveiled its new range of bamboo deckings ... for these natural items; they are now available at ... most people, it is hard to overstate the significance ... of attention to online services. The company’s workers are ...
(Date:10/19/2014)... Having been working in the garment industry ... customer needs. According to James, one of the company’s top ... or with high-low skirts that add beauty to them. Chiffon ... LunaDress has unveiled its new selection of 2014 long prom ... brand new items are available in over 20 popular designs. ...
(Date:10/19/2014)... a professional company of women’s dresses and related accessories, ... dresses . All the company’s old and new client ... up to 66 percent off. , SweetDressy.com is ... Its dress specialists are striving to make more trendy ... world. All the company’s items are unique, graceful and ...
(Date:10/19/2014)... 19, 2014 (HealthDay News) -- New stem cell-based research ... to new treatments, a new study suggests. Scientists ... intestinal tissue in a lab dish. They then transplanted ... studying intestinal disorders, according to the researchers. "This ... and conditions that can cause intestinal failure, from genetic ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
... Margaret Steele HealthDay Reporter , WEDNESDAY, Feb. ... notable decreases throughout most states and across all racial ... Forty-five states reported significant declines in births to ... 2009. Thirty-one states also reported fewer births to 15-to-17-year-olds ...
... (HealthDay News) -- The earlier a person begins puberty, the ... new study suggests. The research was based on 78 ... they began puberty until they reached sexual maturity. The investigators ... at puberty onset, with greater bone mass linked to early ...
... Feb. 2 (HealthDay News) -- Electrical stimulation of the ... help people solve new, difficult problems, research suggests. ... stimulation of the brain,s anterior temporal lobes were three ... a challenging, unfamiliar problem than participants in a control ...
... 2 (HealthDay News) -- In families where dads play ... more supportive of each other,s parenting styles. But ... have more disagreements than couples in which mom is ... University study included 112 Midwestern couples with a 4-year-old ...
... Doheny HealthDay Reporter , WEDNESDAY, Feb. 2 (HealthDay ... a daughter,s chances of not only having a stroke but ... shows. "Our new study shows that stroke in mothers ... Banerjee, a clinical research associate at the Stroke Prevention Research ...
... The huge winter storm producing up to two feet of ... also cause a blizzard of injuries if people don,t take ... the American Academy of Orthopaedic Surgeons warns. "Shoveling snow ... wet, heavy snow. It may be especially vigorous for people ...
Cached Medicine News:Health News:United States Sees Record Drop in Teen Births From 2007-09 2Health News:United States Sees Record Drop in Teen Births From 2007-09 3Health News:Early Puberty Onset Linked to Stronger Bones 2Health News:Parents Have Stronger Relationship When Dad Plays With Kids 2Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 2Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 3Health News:Take Safety Precautions in the Snow, Ice 2
... IgM Capture ELISA is for the qualitative ... recombinant antigens (WNRA) in serum as an ... West Nile virus infection in patients with ... must be confirmed by Plaque Reduction Neutralization ...
... Used for dilation of urethral ... of the bladder. The flare ... the catheter fits a standard ... is threaded to attach to ...
Used to dilate the male or female urethra to treat stricture disease. Supplied sterile in peel-open packages. Intended for one-time use....
The removable inflation adapter allows the ureteroscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: